LN2222

LN2222 is an investigational small molecule prokinetic agent being developed by Shandong New Era Pharmaceutical, a subsidiary of Lunan Pharmaceutical Group. It is currently in Phase I clinical development in China for the treatment of postoperative gastrointestinal dysfunction (PGD). The drug is administered intravenously and is being evaluated for its safety, tolerability, and pharmacokinetics in comparison to oral prucalopride succinate. Based on this clinical comparison, LN2222 likely acts as a selective 5-hydroxytryptamine receptor 4 (5-HT4) agonist, a mechanism known to stimulate gastrointestinal motility and accelerate gastric emptying, which is critical for managing ileus and other forms of gastrointestinal dysfunction following surgery.